Capsule Summary Slidesets

Share

Program Content

Activities

  • LOXO-292 in <i>RET</i>+ Tumors
    LIBRETTO-001: Phase I Trial of LOXO-292, a Novel RET Inhibitor, in Patients With RET-Altered Advanced Solid Tumors
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 05, 2018

    Expires: June 04, 2019

  • Pembrolizumab in Stage III NSCLC
    LUN 14-179: Phase II Trial of Concurrent Chemoradiation Followed by Consolidation Pembrolizumab in Unresectable Stage III NSCLC
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 05, 2018

    Expires: June 04, 2019

  • DREAM: Durvalumab in Mesothelioma
    DREAM: Phase II Trial of First-line Combination Durvalumab Plus Chemotherapy in Advanced Mesothelioma
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 06, 2018

    Expires: June 05, 2019

  • Nivo + CT in PD-L1–Low NSCLC
    CheckMate 227: First-line Nivolumab + CT vs Nivolumab + Ipilimumab vs CT in Patients With NSCLC and < 1% PD-L1 Expression
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 07, 2018

    Expires: June 06, 2019

  • CCGA: Lung Cancer Detection by cfDNA
    CCGA: Interim Analysis of Observational Study to Detect Early-Stage Lung Cancer Noninvasively via Genomewide Sequencing of Plasma Cell-Free DNA
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 07, 2018

    Expires: June 06, 2019

  • IMpower131: Atezolizumab + CT in SqNSCLC
    IMpower131: First-line Atezolizumab + Carboplatin/Pac or nab-Pac vs Carboplatin/nab-Pac in Advanced Squamous NSCLC
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 11, 2018

    Expires: June 10, 2019

  • IMpower150: Atezo + CT + Bev in NSCLC
    IMpower150 Interim OS Analysis: Atezolizumab + CT ± Bevacizumab vs CT + Bevacizumab in Patients With Untreated Advanced Nonsquamous NSCLC
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 12, 2018

    Expires: June 11, 2019

  • ARCHER 1050: OS with Dacomitinib in NSCLC
    Dacomitinib vs Gefitinib in Advanced NSCLC With EGFR-Activating Mutations: Final OS Analysis From the Phase III ARCHER 1050 Trial
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 12, 2018

    Expires: June 11, 2019

  • KEYNOTE-407: Pembro + CT in SqNSCLC
    KEYNOTE-407: Phase III Trial of Carboplatin + Paclitaxel/Nab-Paclitaxel ± Pembrolizumab in Patients With Untreated Stage IV Squamous NSCLC
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 13, 2018

    Expires: June 12, 2019

  • KEYNOTE-042: First-line Pembro vs CT in Adv NSCLC With PD-L1 ≥ 1%
    KEYNOTE-042: First-line Pembrolizumab vs Platinum-Based Chemotherapy for Advanced or Metastatic NSCLC With PD-L1 TPS ≥ 1%
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 13, 2018

    Expires: June 12, 2019

  • Pembrolizumab in SCLC
    Phase II KEYNOTE 158: Pembrolizumab in Advanced Small-Cell Lung Cancer
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 13, 2018

    Expires: June 12, 2019

Provided by

ProCE Banner

Supporters

Amgen, Inc.

Astellas Text

AstraZeneca

Celgene

Eisai

Genentech TEXT Only

Janssen

Merck Oncology

Seagen